Gram-positive Bacterial Infections Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Gram-positive Bacterial Infections Market is segmented by Drug Type, Disease, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography

Market Snapshot

gram-positive-bacterial-infections-market_Market Summary
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factor driving the growth of the Gram-positive Bacterial Infections market is the increasing prevalence of the infections because of gram-positive bacteria. Pneumonia is a type of Gram-positive Bacterial Infection that affects the lungs. According to WHO, pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and Sub-Saharan Africa.

Additionally, increasing product approvals for the treatment of the infections, the rising development of Anti-MRSA drugs are also boosting the market growth globally. In October 2018, Paratek Pharmaceuticals, Inc. received U.S. FDA approval for its NUZYRA (Omadacycline)injection, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). However, antibiotic resistance is the major restraint that is hampering the growth of the market.

Scope of the Report

As per the scope of the report, gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. Gram-positive Bacterial Infections include Virulence, Pathogenesis, Immune Response, Inflammatory Response, Drug Resistance. There are several classic gram-positive species that cause disease in humans. The most common organisms include Streptococcus, Staphylococcus, Enterococcus, Bacillus, etc.

By Drug Type
b-Lactam Antimicrobials
Fluoroquinolones
Penicillin
Cephalosporins
RNA Immunoprecipitation (RIP)
Vaccine
Others Drugs
By Disease
Pneumonia
Sepsis
Pharyngitis
Methicillin-resistant Staphylococcus aureus (MRSA) Infections
Endocarditis
Meningitis
Other Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cephalosporins Segment is Found Holding a Significant Market Share During the Forecast Period

Cephalosporins are beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, present in the cell wall of the bacteria. According to the World Health Organization (WHO), this group of antibiotics is considered critically important to human medicine. The cephalosporins are indicated for the treatment of infections caused by Gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis, and cellulitis. They are also used as alternatives to the penicillins in penicillin-allergic patients and for 'mixed' infections caused by Gram-positive organisms.

Cephalosporin has a large share in the antibiotics market, which is partly due to overprescription, and also due to the fact that it is the most widely explored family of antibiotics with over five generations of cephalosporins that have already been developed. Additionally, the companies are involved in the strategic development of new products.

Picture7.png

North America is Found Dominating the Gram-positive Bacterial Infections Market

North America and Europe are the major markets in the Gram-positive Bacterial Infections globally, due to the high prevalence of various types of gram-positive bacterial infections and associated diseases. 

In the United States, antibiotic use among older adults increased, after insurance coverage was expanded through Medicare Part D, particularly, of broad-spectrum antibiotics. Increasing product launches are anticipated to drive the gram-positive bacterial infections market in the North America region. For instance, in March 2017, Pfizer launched a combination of Avibactam and Ceftazidime drug Zavicefta, for the treatment of intraabdominal infections.

Picture6.png

Competitive Landscape

The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. Some of the market players are GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., etc. among others. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 RisingPrevalence of Gram-positive Bacterial Infections

      2. 4.2.2 Increasing Number of Drug Approvals

    3. 4.3 Market Restraints

      1. 4.3.1 Antibiotic Resistance

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 b-Lactam Antimicrobials

      2. 5.1.2 Fluoroquinolones

      3. 5.1.3 Penicillin

      4. 5.1.4 Cephalosporins

      5. 5.1.5 RNA Immunoprecipitation (RIP)

      6. 5.1.6 Vaccine

      7. 5.1.7 Others Drugs

    2. 5.2 By Disease

      1. 5.2.1 Pneumonia

      2. 5.2.2 Sepsis

      3. 5.2.3 Pharyngitis

      4. 5.2.4 Methicillin-resistant Staphylococcus aureus (MRSA) Infections

      5. 5.2.5 Endocarditis

      6. 5.2.6 Meningitis

      7. 5.2.7 Other Diseases

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline Plc

      2. 6.1.2 Johnson & Johnson Inc.

      3. 6.1.3 Merck & Co. Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 AstraZeneca

      6. 6.1.6 Cumberland Pharmaceuticals

      7. 6.1.7 Novartis AG

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Sun Pharmaceutical Industries Ltd.

      10. 6.1.10 Cipla Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Gram-positive Bacterial Infections Market market is studied from 2018 - 2026.

The Gram-positive Bacterial Infections Market is growing at a CAGR of 8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

GlaxoSmithKline PLC, Sun Pharmaceutical Industries Ltd., Merck & Co. Inc., Novartis AG, Cumberland Pharmaceuticals are the major companies operating in Gram-positive Bacterial Infections Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!